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Background: In response to diverse genotoxic stimuli p53 is activated as transcription factor to exert its
tumor-suppressor function. P53 activation requires protein stabilization, nuclear localization and posttranslational
modifications in key residues that may influence p53 selection of target genes. Among them, serine 46 (Ser46)
phosphorylation is considered specific for apoptotic activation. Hyperglicaemia, the high blood glucose condition,
may negatively affect tumor response to therapies through several mechanisms, conferring resistance to drug-induced
cell death. However, whether high glucose might modify p53Ser46 phosphorylation has never been addressed.
Methods and results: Here, we performed biochemical and molecular analyses in different cancer cell lines
treated with chemotherapy in the presence or absence of high glucose condition. Analyses of p53 posttranslational
modifications showed that drug-induced p53Ser46 phosphorylation was reduced by high glucose. Such reduction
depended by high glucose-induced calyculin A-sensitive phosphatase(s), able to specifically target p53Ser46
phosphorylation. The specific effect on Ser46 phosphorylation was addressed by analysing Ser15 phosphorylation
that instead was not modified by high glucose. In agreement, a constitutively phosphorylated Ser46D p53 mutant
was resistant to high glucose. As a consequence of phosphoSer46 impairment, high glucose reduced the tumor
cell response to drugs, correlating with reduced p53 apoptotic transactivation. The drug-induced apoptotic cell
death, reduced by high glucose, was finally restored by the phosphatase inhibitor calyculin A.
Conclusions: These data indicate that high glucose specifically inhibited Ser46 phosphorylation thus reducing
p53 apoptotic activity. These results uncover a new mechanism of p53 inactivation providing an interesting novel
molecular link between metabolic diseases such as diabetes or obesity and tumor progression and resistance to
therapies.
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Gene transcriptionBackground
P53 is the major tumor-suppressor that functions within
an extensive signalling network [1]. In response to sev-
eral types of genotoxic stress p53 is activated to control
genes that lead to different cellular outcome such as
cell-cycle arrest and apoptosis. In this manner, p53 pro-
tects cells from tumorigenesis, reduces tumor progres-
sion, and activates tumor cell response to anticancer
drugs [2]. P53 activation is achieved at multiple levels in-
cluding protein stability and sub-cellular localization* Correspondence: gdorazi@unich.it
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article, unless otherwise stated.leading to transcriptional activation of sequence-specific
target genes with specific oncosuppressor functions [3].
Apoptosis has been suggested to be a major contribution
to p53-mediated suppression of tumor formation [4] and
resistance to apoptosis is one of the major hurdles in the
treatment of cancer [5]. TP53 posttranslational modifica-
tions, such as phosphorylation and acetylation of specific
residues, are thought to play a role for the choice among
the different biological functions regulated by p53 [6]. It
has been proposed that phosphorylation of p53 at N-
terminal serine 46 (Ser46) is a necessary step for indu-
cing apoptosis in response to severe DNA damage by
shifting from cell-cycle-related to apoptosis-related gene
transcription [7,8]. P53 phosphorylated at Ser46 modu-
lates less sensitive gene regulatory elements such asentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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including p53AIP1, PIG3, Bax, Noxa, Puma and KILLER/
DR5 [7,9-12], or the antiapoptotic factor galectin-3 [13],
leading to irreversible apoptosis. To add a layer of com-
plexity, some studies have shown that p53 Ser46 phos-
phorylation is dispensable for transcriptional activation
[14]. However, a defect in Ser46 phosphorylation has been
observed in tumor cells that are resistant to p53-mediated
apoptosis, and this defect contributes to chemoresistance
or the acquisition of the resistance to p53 gene transfer
[15]. On the contrary, a mutant active form of p53, in
which Ser46 is replaced with phenylalanine (p53-46 F),
has been shown to induce apoptosis more effectively that
wild-type (wt) p53 [16], while studies with knock-in mice
expressing the human TP53 gene with Ser46A mutation
(non phosphorylatable Ser46), reduced p53 apoptotic
transactivation [17], strengthening the apoptotic role for
this p53 posttranslational modification.
Hyperglicaemia is a pathophysiological condition char-
acterized by high blood glucose concentration that has
been shown to predispose to cancer development and
progression [18]. Hyperglicaemia is often a consequence
of a Western lifestyle that is associated with metabolic
syndrome and type-2 diabetes or obesity. Epidemio-
logical evidence suggests that patients with diabetes mel-
litus are at significantly higher risk of developing many
types of cancers [19]. Foods with high glycemic load
are most closely correlated with higher recurrence of
colon cancer [20]. Moreover, hyperglicaemia may in-
hibit tumor response to therapies conferring resistance
to chemotherapy-induced cell death [21-24]. Glucose
metabolism has been shown to reduce p53-dependent
transcription of apoptotic Puma gene, although the mo-
lecular mechanism of such inactivation was not eluci-
dated [25]. Therefore, in this study we sought to
investigate in vitro whether high glucose (HG) culture
condition might target p53Ser46 in cancer cells and
have an impact on p53-induced drug response.
Materials and methods
Cell culture and reagents
In this study human lung cancer H1299 (p53 null), colon
cancer RKO and HCT116 (carrying wild-type p53),
HCT116-p53-/-, lung cancer A549 and ovarian cancer
2008 cells (carrying wild-type p53), were used. Cells
were routinely cultured in DMEM (Life Technology-
Invitrogen) containing 1 g/L D-glucose, supplemented
with 10% heat-inactivated fetal bovine serum (FBS) plus
glutamine and antibiotics. For high glucose (HG) treat-
ment, cells were transferred to DMEM containing 4.5 g/L
D-glucose (Life Technology-Invitrogen), as previously re-
ported [22,23], supplemented with 2% FBS for 24 h before
adding chemotherapeutic drugs Adriamycin (ADR) or cis-
platin (CDDP) to the culture media respectively at 2 μg/mland 5 μg/ml for additional 16 h (for ChIP assay) or 24 h
(for all the other experiments). Phosphatase inhibitor caly-
culin A [26] (Sigma) was added at 1 nM along with drugs.
Viability and tunel assays
For viability assay, subconfluent cells were plated in du-
plicate in 60 mm Petri dishes and 24 h later transferred
to HG medium or DMEM with 1 g/L D-glucose, both
containing 2% FBS. The day after, cells were treated with
ADR or CDDP for 24 hours. Both floating and adherent
cells were collected and cell viability was determined by
Trypan blue exclusion by direct counting with a haemo-
cytometer, as reported [27].
Tunel assays were essentially performed as described
[28]. Briefly, 4x104 cells were spun on a slide by cytocen-
trifugation and subsequently fixed in 4% paraformald-
heyde for 30 min at room temperature. After rinsing
with PBS, the samples were permeabilized in a solution
of 0.01% Triton X-100 in sodium citrate for 2 min. Sam-
ples, washed with PBS, were then incubated in the
TUNEL reaction mix for 1 h at 37°C according to the
manufacture’s instructions (Roche, Germany). Cells were
counter-stained with Hoechst 33342 before analysis with
a fluorescent microscope (Zeiss).
Chromatin-immunoprecipitation (ChIP) assay
ChIP assay was carried out essentially as previously de-
scribed [29]. Protein complexes were cross-linked to
DNA in living cells by adding formaldehyde directly to
the cell culture medium at 1% final concentration. Chro-
matin extracts containing DNA fragments with an aver-
age size of 500 bp were incubated overnight at 4°C with
milk shaking using polyclonal anti-p53 antibody (FL393,
Santa Cruz Biotechnology). Before use, protein G (Pierce)
was blocked with 1 μg/μL sheared herring sperm DNA and
1 μg/μL BSA for 3 h at 4°C and then incubated with chro-
matin and antibodies for 2 h at 4°C. PCR was performed
with HOT-MASTER Taq (Eppendorf) using 2 μL of immu-
niprecipitated DNA and promoter-specific primers. Immu-
noprecipitation with non-specific immunoglobulins (IgG;
Santa Cruz Biotechnology) was performed as negative con-
trols. The amount of precipitated chromatin measured in
each PCR was normalized with the amount of chromatin
present in the input of each immunoprecipitation. PCR
products were run on a 2% agarose gel and visualized by
ethidium bromide staining using UV light.
Transfection and luciferase assays
Cells were transiently transfected with the cationic polymer
LipofectaminePlus method (Invitrogen) according to the
manufacturers’ instructions. Luciferase activity was mea-
sured in H1299 cells co-transfected with β-galactosidase
(β-gal), wtp53 or the constitutively phosphorylated
p53Ser46D expression vectors, along with the synthetic
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Luciferase activity was assayed on whole cell extracts
and the luciferase values normalized to β-gal activity
and protein content and expressed as relative luciferase
unit (RLU), as previously described [29].
RNA extraction and semi-quantitative reverse transcription
(RT)-PCR analysis
Cells were harvested in TRIzol Reagent and total RNA
was isolated following the manufacturer’s instructions
(Invitrogen). The first strand cDNA was synthesized
from 2 μg of total RNA with MuLV reverse transcriptase kit
(Applied Biosystems). Semi-quantitative Reverse-Transcribed
(RT)-PCR was carried out by using Hot-Master Taq
polymerase (Eppendorf ) with 2 μl cDNA reaction and
genes specific oligonucleotides under conditions of linear
amplification. PCR products were run on a 2% agarose gel
and visualized with ethidium bromide. The housekeeping
28S gene, used as internal standard, was amplified from
the same cDNA reaction mixture. Densitometric analysis
was applied to quantify mRNA levels compared to control
gene expression.
Western blotting
Western immunoblotting derived from whole cell lysates
or nuclear/cytoplasmic extracts was performed as previ-
ously described [30]. Total cell extracts were prepared
by incubation in lysis buffer (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 5 mM EDTA, 150 mM KCl, 1 mM di-
thiothreitol, 1% Nonidet P-40) and a mix of protease
inhibitors and resolved by 9-12% SDS-polyacrilamide
gel electrophoresis. Proteins were transferred to a poly-
vinylidene difluoride membrane (PVDF, Millipore) and
membranes were blocked with 5% nonfat dry milk in
PBS and incubated with the primary antibodies followed
by an anti-immunoglobulin–G-horseradish peroxidase
antibody (BioRad).
For subcellular fractionation, cells were trypsinized,
rinsed with PBS and collected by centrifugation. Cells
were then suspended in hypotonic buffer (10 mM
HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA) and placed on ice for 15 min. NP40 was added
to a final concentration of 0.5%. Cells were spun top
speed for 30 s before the supernatant (cytoplasmic frac-
tion) was collected. The remaining pellet was washed
with hypotonic buffer, resuspended in RIPA buffer, soni-
cated and spun at 14000 g for 15 min to remove debris
and collect the supernatant (nuclear fraction). We con-
firmed the separation of the cytoplasmic and nuclear frac-
tions by Western immunoblotting of tubulin (cytoplasmic
marker) and lamin A (nuclear marker), respectively.
The following primary antibodies were used: mouse
monoclonal p53 (DO1) (Santa Cruz Biotechnology), rabbit
polyclonal phospho-Ser46 (Cell Signalling and Santa Cruz)and phospho-Ser15 (Cell Signalling), mouse monoclonal
anti-poly(ADP-ribose) polymerase (PARP, cleaved form,
BD Pharmingen), rabbit polyclonal anti-lamin A and
mouse monoclonal anti-β-actin (Santa Cruz), followed
by an anti-immunoglobulin-G-horseradish peroxidase
secondary antibody (BioRad). Immunoreactivity was de-
tected by enhanced chemiluminescence (ECL) (Amersham
GE Healthcare).
Statistics
Each experiment, unless specified, was performed at least
three times. All experiments results were expressed as the
arithmetic mean; standard deviation (S.D.) of measure-
ment was shown. Student’s t test was used for statistical
significance of the difference between groups. Statistical
analysis was performed using analysis of variance at 5%
(p ≤ 0.05) or 1% (p ≤ 0.01).
Results
Glucose reduces chemotherapy-induced cell death
To look into the influence of high glucose (HG) levels
on resistance to chemotherapeutic agents, several hu-
man cancer cells, carrying wild-type (wt) p53, including
RKO and HCT116 colon cancer, 2008 ovarian cancer
and A549 lung cancer cells, were incubated with chemo-
therapeutic drugs, such as adryamicin (ADR) or cisplatin
(CDDP), before or after treatment with HG (4.5 g/L D-
glucose) condition. The 4.5 g/L and the 1 g/L D-glucose
concentration for, respectively, high glucose (HG) and
low glucose condition were chosen according to previous
studies [22,23]. Cancer cell death induced by apoptotic
doses of chemotherapy, as previously reported [10,31],
was significantly reduced when cells were transferred into
HG culture condition (Figure 1A). Of note, HG per se did
not modify cancer cell viability, indicating that it was in-
stead triggering molecular mechanisms of resistance to
antitumor drugs. To verify that HG might target p53 ac-
tivity, HCT116-p53-/- cells were tested in comparison with
wtp53-carrying cells. Cell viability assay shows that the
slight drug-induced cell death in HCT116-p53-/- cells was
not modified by HG condition (Figure 1A), suggesting
that p53 inhibition might have a role in HG-induced che-
moresistance. Moreover, the ADR-induced cleavage of the
apoptotic marker PARP was strongly reduced by HG con-
dition (Figure 1B).
HG reduces p53 apoptotic transactivation
Therefore, to evaluate the influence of HG on p53 activ-
ity we first analysed the p53/DNA binding activity by
ChIP assay and, after that, p53 transactivation. We
found that the efficient p53 in vivo recruitment onto
apoptotic p53AIP1 and Puma promoters in response to
ADR was strongly reduced by HG culture condition
(Figure 2A). On the other hand, HG did not modify the
Figure 1 High glucose (HG) culture condition reduces the
cytotoxic effects of drugs in wtp53-carrying tumor cells. (A) Cells
were plated at subconfluence in culture media containing 10% FBS
and 1 g/L D-glucose. The day after, medium was changed with a
medium containing 2% FBS with either 1 g/L D-glucose or 4.5 g/L
D-glucose, respectively low and high glucose (HG), for 24 h before
adding chemotherapeutic drugs Adriamycin (ADR) (to RKO, HCT116
and HCT116-p53-/- cells) at 2 μg/ml or cisplatin (CDDP) (to A549 and
2008 cells) at 5 μg/ml. Twenty-four hours later, the percentage of dead
cells was scored by trypan blue staining. Error bars show standard
deviation. *P = 0.002. (B) HCT116 cells were treated with ADR (2 μg/ml)
with or without HG culture condition. Equal amount of total cell
extracts was analysed by western immunoblotting with anti-PARP
antibody specific for the cleaved form (cleav). Anti-β-actin was used as
protein loading control.
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p21, and p53R2 (Figure 2A). The p53 transcriptional ac-
tivity was then evaluated by luciferase assay following
transient co-transfection of H1299 cells with the syn-
thetic p53 responsive PG13-luc reporter and wtp53 ex-
pression vector. As shown in Figure 2B, p53 induced
PG13-luc activity that was remarkably reduced by HG con-
dition. In a similar manner, HG reduced the p53-induced
transcriptional activity of the natural p53AIP1-luc reporter
(Figure 2B). In vivo analyses of mRNA levels show that
drug-induced upregulation of p53 apoptotic target genes
such as p53AIP1 and Puma was strongly impaired by
HG condition, while p21 expression was not modified(Figure 2C). These results indicate that p53 apoptotic tran-
scriptional activity was impaired by HG culture condition.
HG does not impair p53 nuclear translocation, rather it
reduces serine 46 (Ser46) phosphorylation
To identify the mechanism underlying impaired p53
apoptotic activity in HG condition, we first examined
p53 stability and nuclear localization, which are at the
basis of p53 transcriptional activation [6]. Western blotting
of nuclear and cytoplasmic cell extracts show that p53
underwent efficient stabilization and nuclear localization
following drug treatment, and both conditions were not
modified by HG (Figure 3A). These results indicate that
the impaired p53 binding to apoptotic promoters follow-
ing HG, seen above, does not depend on defect of p53 nu-
clear accumulation. Therefore, we next sought to evaluate
whether p53 posttranslational modifications were targeted
by HG. In particular, we analysed Ser46 phosphorylation
(p-Ser46), since p53AIP1 is a specific target of p-Ser46 [7]
and we found above that p53AIP1 expression was inhib-
ited by HG. Western blotting of total cell extracts with
phospho-specific antibodies show that drug-induced p-
Ser46 was strongly reduced by HG condition (Figure 3B).
The specific effect of HG on p-Ser46 was addressed by
analysing p-Ser15 that, in comparison, was not modi-
fied (Figure 3B). Moreover HG did not alter p53 levels
(Figure 3B), indicating that it specifically affected p53Ser46
phosphorylation. In support of our hypothesis that p-Ser46
is a target of HG, we analysed p53AIP1-luc promoter
activity following transfection of a constitutively phos-
phorylated p53Ser46D expression vector. The results show
that p53AIP1-luc activity, induced by Ser46D expression,
was not inhibited by HG condition, compared to the wtp53-
induced p53AIP1-luc activity (Figure 3C). These data indi-
cate that HG specifically inhibited Ser46 phosphorylation
though reducing p53-induced apoptotic luciferase activity.
Inhibition of HG-induced phosphatase(s) by the use of
calyculin A restores p-Ser46
The above data show that dephosphorylation of p53 at
the key Ser46 residue limited p53 apoptotic transcrip-
tional activity. To get insight into the mechanism of
Ser46 dephosphorylation by HG we used calyculin A, a
cell-permeable phosphatase inhibitor which has been
shown to enhance ionizing radiation-induced p-Ser46
[26]. Western blotting show that drug-induced p-Ser46,
strongly reduced by HG, was efficiently rescued by calycu-
lin A (Figure 4A). At molecular level, ADR-induced p53
apoptotic-gene expression, inhibited by HG, was rescued
by calyculin A (Figure 4B). These data suggest that one or
more calyculin A-sensitive phosphatases were triggered by
HG to deregulate drug-induced p-Ser46 of p53; however,
as calyculin A not only counteracted the negative effect of
HG on p53 transactivation but further increased it, it is
Figure 2 High glucose (HG) culture condition reduces the p53/DNA binding and transactivation functions mainly on apoptotic genes.
(A) ChIP analyses performed with anti-p53 antibody on HCT116 cells treated with ADR (2 μg/ml) in 2% FBS culture medium with or without HG.
PCR analyses were performed on the immunoprecipitated DNA samples using specific primers for the p53 target promoters. A sample representing
linear amplification of the total chromatin (Input) was included as control. Additional controls included immunoprecipitation performed with
nonspecific immunoglobulins (No Ab). (B) H1299 cells were transiently co-transfected with PG13-luc or p53AIP1-luc reporters and wtp53
plasmid. Twenty-four hours after transfection culture medium was changed with a medium containing 2% FBS with or without HG. Results,
normalized to β-gal activity are the mean ± S.D. of three independent experiments performed in duplicate. *P = 0.001. (C) RNA samples were
extracted by HCT116 cells treated as in Figure 1 and used for RT-PCR. The mRNA level of specific p53 target genes was analysed by densitometry and
plotted as the expression ratio to control 28S expression. Data are the mean ± S.D. of two independent experiments. *P = 0.001.
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independently of HG condition. Previous studies, includ-
ing ours, have shown that phosphorylation of p53 at Ser46
activates the apoptotic cascade [7,9,10,14,16], therefore,
we investigated the effect of HG on drug-induced apop-
totic cell death by Tunel staining. We found that theADR-induced Tunel positivity was reduced by HG con-
dition and efficiently rescued by calyculin A treatment
(Figure 4C). These results indicate that HG dephos-
phorylated Ser46 in p53 likely through activation of one
or more calyculin A-sensitive phosphatases that im-
paired p53 apoptotic activity.
Figure 3 High glucose (HG) culture condition does not affect drug-induced p53 stability and nuclear localization, rather it inhibits
p53Ser46 phosphorylation. (A) HCT116 and A549 cells were treated with ADR (2 μg/ml) or CDDP (5 μg/ml), respectively, with or without HG
culture condition. Equal amount of nuclear and cytoplasmic extracts was analysed by western immunoblotting with specific anti-p53 antibody.
Anti-lamin A and anti-tubulin antibodies were used as control of efficient nuclear and cytoplasmic extraction, respectively. (B) HCT116, 2008
and A549 cells were treated with ADR or CDDP, as shown, with or without HG. Equal amount of total cell extracts was analysed by western
immunboltting with phospho-specific Ser46 and Ser15 antibodies and total p53 antibody. Anti-β-actin was used as protein loading control.
(C) H1299 cells were transiently co-transfected with p53AIP1-luc reporter and wtp53 or Ser46D mutant plasmids. Twenty-four hours after
transfection culture medium was changed with a medium containing 2% FBS with or without HG. Results, normalized to β-gal activity are the
mean ± S.D. of three independent experiments performed in duplicate. *P = 0.001; NSS: not statistically significant.
Garufi and D’Orazi Journal of Experimental & Clinical Cancer Research 2014, 33:79 Page 6 of 10
http://www.jeccr.com/content/33/1/79Discussion
Here, for the first time a novel glucose-mediated mechan-
ism of p53 inhibition was shown: HG culture condition
impaired p53Ser46 phosphorylation and consequently re-
duced p53 apoptotic activity, attenuating drug-inducedcell death. Importantly, the use of the phosphatase inhibi-
tor calyculin A was sufficient to restore Ser46 phosphoryl-
ation and drug-induce cell death, indicating that Ser46
dephosphorylation was the mechanism of inhibition of
p53 apoptotic activity following HG condition.
Figure 4 High glucose (HG) induces calyculin A-sensitive phospahatase(s) able to target p-Ser46. (A) HCT116, cells were treated with ADR
with or without HG; phosphatase inhibitor calyculin A was added at 1 nM along with ADR. Equal amount of total cell extracts was analysed by
western immunboltting with phospho-specific Ser46 antibody and total p53 antibody. Anti-β-actin was used as protein loading control. (B) RNA
samples were extracted by HCT116 cells treated as in (A) and used for RT-PCR of p53 target gene expression. 28S levels were analyzed as internal
control (left panel). Densitometric analysis is shown in the right panel and plotted as the expression ratio to control 28S expression. (C) Tunel
assay of HCT116 and 2008 cells treated with ADR and CDDP, respectively, with or without HG condition. Phosphatase inhibitor calyculin A was
added at 1 nM along with drugs. The results shown are the percentage of Tunel positive cells and are representative of two independent
experiments performed in duplicates, ± S.D. *P = 0.001.
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ciated with the prognosis, progression, and therapeutic re-
sponse of tumors [32]. P53 is the most inactivated tumor-
suppressor in cancers, therefore, understanding the many
ways of p53 regulation is physiologically important be-
cause it may affect tumor prognosis and therapy [33].
Thus, many studies in the last years have addressed the re-
activation of mutant p53 (see ref. [34,35] and refs. herein)
or the reconstitution of wtp53 [36-39] because tumors
containing wtp53 are usually more sensitive to radiother-
apy or chemotherapy than those bearing inactive p53 [40].
TP53 is mainly mutated, however, other inactivationinvolve p53 protein deregulation. In this regard, the
present results support a significant conceptual advance in
the area of p53 protein inactivation even in the absence of
p53 mutations. Human p53 harbors an array of serine/
threonine phosphorylation sites that span the entire pro-
tein but are mainly concentrated in the N-terminal trans-
activation domain and the C-terminal regulatory domain
Each site/modification may fine-tune p53 function, dictat-
ing p53 activity in a promoter-specific manner [41]. Ser46
has recently been the focus of much attention because it
has been associated with p53 apoptotic function and its
inhibition associated with increased chemoresistance
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also deduced by the codon 47 polymorphism that, al-
though rare, has been shown to interrupt Ser46 phosphor-
ylation and decrease p53-dependent apoptotic activity [42].
Glucose metabolism has been shown to impact p53
function. Glucose restriction can activate p53 apoptotic
pathway [43] that is indeed inhibited in cells lacking a
functional p-Ser46 [44] and can reduce mutant p53 pro-
oncogenic function [45], in line with the beneficial anti-
tumor effect of caloric/dietary restriction [46]. On the
other hand, high glucose has been shown to reduce p53-
dependent transcription of apoptotic Puma gene, al-
though the molecular mechanism of such inactivation
was not elucidated [25]. Here we show that one or more
calyculin A-sensitive phosphatases were induced by HG
to target p53 at Ser46 thus reducing tumor cell response
to anticancer drugs. Further studies will be needed to
elucidate the phosphate(s) involved in p53Ser46 inactiva-
tion by HG and develop a way to block it, as potential
application in clinical practice. In this regard, high glu-
cose has been shown to activate PP2A [47] which has
been shown to dephosphorylate p53 at Ser46 [26], mak-
ing it a good candidate to be analysed in future studies.
Moreover, the partial recovery of drug-induced apop-
tosis following the rescue of p-Ser46, suggests that add-
itional mechanisms of chemoresistance triggered by
HG might exist and negatively impact the tumor re-
sponse to therapies.
In addition, our findings raise more questions for fur-
ther studies; for example, it would be interesting to in-
vestigate whether the HG-induced phosphatase directly
dephosphorylates p53Ser46 or rather it targets the up-
stream kinases claimed to phosphorylate p53 at Ser46, such
as homeodomain-interacting protein kinase 2 (HIPK2)
[9], ATM [48], DNA-dependent protein kinase [49],
protein kinase C δ [50], and dual-specificity tyrosine-
phosphorylation-regulated kinase 2 (DYRK2) [51]. Such
redundancy in kinases able to phosphorylate p53 at
Ser46 support its key role in apoptosis. The possibility
that HG might inhibit one of those kinases, rather than
targeting directly Ser46, comes from the result that
Ser46 phosphorylation is not completely abolished by
HG (Figure 3B, Figure 4A). One of the most studied
Ser46 kinase, also by us, is HIPK2 which is activated by
several cellular stress including chemotherapeutic agents
and whose inhibition has been shown to profoundly re-
strain p53 apoptotic activity. As HIPK2 inhibition impairs
Ser46 but also Lys382 acetylation it would be interesting
to evaluate the effect of HG on p53 acetylation and its im-
pact on drug response [52,53]. It has been recently shown
that reactive oxygen species (ROS) may inhibit HIPK2
kinase activity [54] and, interestingly, a pathophysiological
condition that induces ROS production is high glucose
[55], strongly supporting more extensive studies about theinvolvement of HIPK2 in p53Ser46 inactivation following
HG condition. In preliminary experiments, thus, we have
found that HIPK2 kinase activity was reduced by HG and
that also Lys382 acetylation of p53 was impaired by HG
(unpublished results).
The acquisition of drug resistance of cancer cells is a
big problem in anticancer therapy because it can block
apoptotic pathways and/or increase the ability to repair
DNA, ensuring the survival of cancer. Understanding
the many mechanisms of drug resistance is therefore the
subject of intense studies [56]. In this regard, our results
show that hyperglycemia may have a negative effect in
cancer treatment by inhibiting p53Ser46 apoptotic activ-
ity. These results may have clinical impact because high-
light how controlling blood glucose levels may have
important therapeutic implications in cancer patients.
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